Sitting in the Press Releases

The future rarely shows up with a launch party. Usually it shows up in a press release on a Monday morning, a webcast at 8:00 a.m. Eastern, and a slide deck that most commercial people never open.

That's how it arrived this year. On 27 April 2026, Intellia Therapeutics reported positive Phase 3 results for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. The company called it a global first for in vivo gene editing. The full data followed in The New England Journal of Medicine.

I've spent more than 22 years in rare disease commercialisation, and my first reaction wasn't about the science. It was about the org chart.

Rare disease teams already live in a small-n world. We count patients by name, not by decile. We know which centre sees which family. Our launches have always run on relationships rather than reach. So you might think one-time gene editing changes less for us than for anyone else.

I think it's the reverse. Rare disease is where one-shot therapy lands first, and it lands on commercial models that were built for chronic, repeat-prescription products. Those models are about to break.

The HAE Signal

Here's what HAELO showed. These are trial facts from Intellia's topline release and the NEJM publication, not my interpretation.

  • Mechanism: lonvo-z is an in vivo CRISPR therapy. It is designed to inactivate the KLKB1 gene, permanently lowering kallikrein and bradykinin.
  • Dose: one 50 mg IV infusion, given in an outpatient setting.
  • Population: 80 patients randomised 2:1 (52 lonvo-z, 28 placebo). Adults and adolescents aged 16 and older with Type I or Type II HAE.
  • Primary endpoint: over the six-month efficacy window (weeks 5 to 28), attacks fell by 87% versus placebo. The mean monthly attack rate was 0.26 versus 2.10 (p<0.0001).
  • Key secondary endpoint: 62% of lonvo-z patients were completely attack-free and therapy-free over that window. On placebo, it was 11%.
  • Context: 71% of patients were on long-term prophylaxis (LTP) at entry, and they had to stop it before dosing. As of the 10 February 2026 data cutoff, every patient who had received lonvo-z remained LTP-free.
  • Safety: the most common adverse events were infusion-related reactions, headache and fatigue. NEJM reports no serious or grade ≥3 adverse events in the lonvo-z arm.
  • Regulatory: Intellia has started a rolling BLA with the FDA. If approved, the company expects a US launch in the first half of 2027.
62%
of lonvo-z patients were completely attack-free and therapy-free over the six-month efficacy window, versus 11% on placebo (HAELO, NEJM 2026).

Read that secondary endpoint again. Most patients didn't just have fewer attacks. They had none, and they took nothing else. In HAE, a disease that has been managed for years with chronic prophylaxis and on-demand rescue, that's a different product category.

A caveat belongs here. Six months is not a lifetime, and median follow-up at the cutoff was 7.5 months. Durability, long-term safety and real-world uptake still need to be proven. But the commercial question no longer waits for those answers, because launch planning for a 1H 2027 US date is already underway.

The Platform Signal (Briefly)

One HAE dataset could be a one-off. It isn't the only one.

In May 2026, Lilly reported Phase 1b Heart-2 data for VERVE-102, a base editor that targets PCSK9 in the liver. The results were published in NEJM at the same time. In 35 participants with heterozygous familial hypercholesterolaemia or premature coronary artery disease, one infusion cut LDL-C by up to 62% at the top 1.0 mg/kg dose. The reductions appeared durable through follow-up, which ran at least a year in 15 participants and up to 18 months in some.

This isn't a rare disease launch story, and I'm not presenting it as one. I mention it as a platform signal. Two different editing approaches, in two different liver targets, both show that "one and done" can hold over time. For commercial planners, that means HAE won't be the last indication where a single dose replaces a chronic regimen.

The Pattern: The Body as Software

This is the frame I keep coming back to, and it's my commercial interpretation, not a claim from either trial.

For decades, rare disease therapy has looked like a subscription: a monthly infusion, a weekly injection, a daily pill, refills and adherence programmes. Gene editing looks more like a software patch. You deploy once and then you monitor.

When the update cycle gets shorter, the people who feel it first are the ones with the smallest installed base. Orphan populations are where one-shot therapies get their first deployment, because unmet need is high, endpoints are clean and the patients can be found.

HAE today. Other monogenic liver-driven conditions are likely next (again, my judgment).

That changes the economics of everything downstream.

What Breaks in the Old Commercial Playbook

From where I sit, four things stop working.

01

Patient Identification Becomes a One-Time Window

In a chronic model, a diagnosed patient is a long-term relationship. In a one-time model, each patient is treated once. My commercial judgment is that the identified, diagnosed, motivated pool will be worked through faster than traditional forecasts assume, and then the curve depends on new diagnoses and switching from existing prophylaxis. Forecasts built on persistence and refill rates mislead you.

02

Specialty Selling Turns Into Centre Enablement

You don't detail a one-time infusion the way you detail a monthly prophylactic. The decision is made once, at an expert centre, after a long conversation between physician, patient and family. Field teams sized for call frequency are oversized for that work. They're also under-skilled for what it really needs: logistics, eligibility, consent and long-term follow-up.

03

The Pricing and Payer Story Flips

Chronic orphan pricing is an annual cost conversation. One-time therapy is a lifetime value conversation, paid up front. European payers have already had this argument over gene therapies, and they'll have it again with editing. HAE adds a specific twist: the comparator is an established chronic prophylaxis market, so the budget-impact model has to show a displacement story, not just an add-on cost. I expect outcomes-based and instalment-style agreements to come up quickly (interpretive, not a sourced prediction).

04

Distribution Stops Being Continuous

Specialty pharmacy, homecare and refill logistics were all built around repeat dispensing. A single outpatient infusion needs a different set-up: qualified treatment sites, scheduling, product handling and multi-year follow-up registries. The commercial value moves from the supply chain to the site network.

What to Rebuild First

If I were advising a rare disease company with a one-time therapy two to three years from launch, here's the order I'd suggest. This is practitioner judgment from orphan launches, not trial evidence.

1. Go-to-market design, before headcount. Start from the patient journey for a single decision, not from a sales-force template. Who identifies the patient? Who confirms eligibility? Who infuses? Who follows up for years? Then size the team. Most of the European launch-readiness work I do starts here, and it applies with more force to one-shot products. (See our approach to orphan drug launches in Europe.)

2. Centre-of-excellence capacity and supply. In small markets like the Benelux, a handful of expert centres will carry the early treatment volume. Their capacity to screen, counsel, infuse and monitor sets the real launch ceiling. Build that with them, early, and make sure supply and site qualification are ready on day one.

3. An early access and named-patient bridge. Between US approval and European reimbursement there will be a gap. Rare disease patients and physicians don't wait quietly through it. A clear early access or named-patient programme (NPP) strategy, aligned with local rules, protects patients and keeps the relationship you'll need at launch. That's my view of the sequence, not a statement about any company's European plans.

4. Interim or fractional commercial leadership. Many emerging biotechs reach the edge of Europe without a country organisation. Hiring a full affiliate for a product that treats each patient once may not make sense. An experienced interim or fractional commercial lead can build the access strategy, the centre network and the payer case, then hand over or scale as the market shows itself. (This is the model behind our interim commercial director work in the Benelux.)

Notice what isn't on the list: a bigger field force, more brand campaigns, more reach. One-shot therapy rewards precision and partnership, which rare disease teams should already be good at. The difference now is that there's no second chance at the relationship.

What to Watch

  1. The FDA decision on lonvo-z. Approval, label wording, and any post-marketing or long-term follow-up requirements will set the template for in vivo editing launches.
  2. European regulatory and HTA routes. How the EMA, and then national HTA bodies including Belgium's, handle a one-time HAE therapy against a mature chronic prophylaxis market.
  3. Durability data. Longer HAELO follow-up and the Heart-2 long-term data will decide whether "one and done" holds up in pricing conversations.
  4. Payment models. Whether European payers and manufacturers settle on outcomes-based, annuity or instalment agreements for one-time editing therapies, and how fast.

Stick Around

Rare disease has always been where medicine tries things first. Small populations, high need and close relationships made us the testing ground for orphan incentives, for gene therapy and for diagnostic AI. One-shot editing is the next thing we'll go through before everyone else.

The science has moved. The commercial models haven't caught up yet. That gap is where the next few years of real work will happen.

Stick around. It's going to get weird.